Sassine leaves Visiomed
Monday, 07 February, 2005
WA biotech Visiomed (ASX:VSG) has replaced retiring CEO Saliba Sassine with William Dolphin, formerly of New Zealand's SpectraNet and patient monitoring equipment company, SonaMed.
Dolphin, who is to take control in April, will be responsible for moving Visiomed's FDA-cleared asthma device, the Funhaler, into commercial production.
The change is one of several to have occurred at CEO level among Australian biotechs this year.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
